TOP > 外国特許検索 > OPHTHALMIC DRUG SUSTAINED RELEASE DEVICE

OPHTHALMIC DRUG SUSTAINED RELEASE DEVICE

外国特許コード F180009471
整理番号 S2016-0590-C0
掲載日 2018年7月31日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP015783
国際公開番号 WO 2017191759
国際出願日 平成29年4月19日(2017.4.19)
国際公開日 平成29年11月9日(2017.11.9)
優先権データ
  • 特願2016-093496 (2016.5.6) JP
発明の名称 (英語) OPHTHALMIC DRUG SUSTAINED RELEASE DEVICE
発明の概要(英語) The present invention addresses the problem of providing a drug sustained release system useful for treatment of eye diseases. Provided is an ophthalmic drug sustained release device comprising, in a hollow container having at least one opening, a drug sealing portion and an intraocular retention gas sealing portion that is provided adjacent to the drug sealing portion, wherein the drug sealing portion is isolated from the opening by the intraocular retention gas sealing portion being interposed between the drug sealing portion and the opening.
従来技術、競合技術の概要(英語) BACKGROUND ART
To reduce the effects of treatment and side effects such as are used for the purpose of drug delivery system. The drug delivery system (controlled release), (1) drug release, (2) to promote drug targeting (targeted) and (3) absorption (absorption through the skin, such as a gene) is divided into. Ophthalmology is (1) being actively researched and developed. For example, non-degradable implant (registered trademark) (a reservoir) as (FDA approval) Vitrasert (cytomegalovirus retinitis (AIDS) for release of ganciclovir) (registered trademark) (FDA approval) or Retisert (non-infectious uveal fluocinolone to flame, the sustained release acetonides), (registered trademark) (FDA-approved) Iluvien (diabetic macular edema for fluocinolone, acetonides sustained release), I-vationTM (overseas in clinical trials) (diabetic macular edema for triamcinolone, acetonides sustained release), NT-0501 (Phase II in the first countries) (retinitis pigmentosa and atrophy age-related macular degeneration with respect to the release of the CNTF), biodegradable implant (registered trademark) as a (monolithic) (FDA-approved) Ozurdex (macular edema release of dexamethasone), microspheres (monolithic) DE-102 as (diabetic macular edema of betamethasone to sustained release) and the like have been developed.
On the other hand, in recent years, the development of therapeutic target molecules, antibodies (e.g. bevacizumab, ranibizumab) a pharmaceutical or gene recombinant fusion glycoprotein preparation (e.g. aflibercept), has been developed (for example pegaputanib) aptamer formulation, age-related macular degeneration, diabetic retinopathy and macular edema associated with retinal vein occlusion, the myopic choroidal neovascularization and a good treatment result is reported.
Incidentally, an example of a slow-release drug Patent Document 1, as shown in 2. Patent Document 1 is, release the drug by the gas pressure generated by the embedded micro-pump is disclosed. On the other hand, Patent Document 2 is a sustained release drug by diffusion in a device for controlled release of the eye.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NAGOYA CITY UNIVERSITY
  • 発明者(英語)
  • YASUKAWA Tsutomu
国際特許分類(IPC)
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close